SAMSARA BIOCAPITAL LLC
Q1 2026 Form 13-F
PALO ALTO, CALIFORNIA
CIK 0001744967
· CRD 288114
· SEC-registered investment adviser
$1.0B Reported Value Total
SAMSARA BIOCAPITAL, LLC reports 3 total accounts under management (AUM). There are 3 discretionary accounts valued at $2,170,095,404, and 0 non-discretionary accounts.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
Private funds (Form ADV)
4 funds
· $2.3B gross asset value
Venture Capital Fund: $2.3B
Source: Form ADV filed 2026-10-28
Reported value
$1.0B
Quarter over quarter
-3.1%
Holdings
22
Top-10 concentration
92.0%
Key People
Form ADV owners & control persons
Srinivas Akkaraju
MANAGER OF SAMSARA BIOCAPITAL, LLC
Jonathan Elliot Cohen
CHIEF OPERATING OFFICER
Patrick Michael Dominguez
CHIEF COMPLIANCE OFFICER
Filing Navigation
13F Metrics
Loading 13F Metrics
Q1 2026 13F record
Q1 2026 13F filing summary
| Period of report | March 31, 2026 |
|---|---|
| Filed | May 15, 2026 |
| Form | 13F-HR |
| Reported value | $1.0B |
| Positions | 22 |
| Change in reported value | +6.2% |
| New positions | 3 |
| Exited positions | 2 |
| Position turnover | 20.8% |
| Top-10 concentration | 92.0% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q2 2026 13F
Filed Aug 14, 2026
|
24 | $1.2B |
|
Q1 2026 13F
Filed May 15, 2026
|
22 | $1.0B |
|
Q4 2025 13F
Filed Feb 17, 2026
|
21 | $969.3M |
|
Q3 2025 13F
Filed Nov 14, 2025
|
27 | $765.9M |
|
Q2 2025 13F
Filed Aug 14, 2025
|
29 | $488.9M |
|
Q1 2025 13F
Filed May 15, 2025
|
37 | $560.8M |
|
Q4 2024 13F
Filed Feb 14, 2025
|
43 | $728.6M |
|
Q3 2024 13F
Filed Nov 14, 2024
|
42 | $520.3M |
|
Q2 2024 13F
Filed Aug 14, 2024
|
40 | $477.8M |
|
Q1 2024 13F
Filed May 15, 2024
|
39 | $646.4M |
|
Q4 2023 13F
Filed Feb 14, 2024
|
41 | $642.8M |
|
Q3 2023 13F
Filed Nov 14, 2023
|
41 | $326.7M |
|
Q2 2023 13F
Filed Aug 14, 2023
|
47 | $569.7M |
|
Q1 2023 13F
Filed May 15, 2023
|
56 | $483.8M |
|
Q4 2022 13F
Filed Feb 14, 2023
|
54 | $464.6M |
|
Q3 2022 13F
Filed Nov 14, 2022
|
55 | $428.9M |
|
Q2 2022 13F
Filed Aug 15, 2022
|
56 | $375.1M |
|
Q1 2022 13F
Filed May 16, 2022
|
56 | $397.2M |
|
Q4 2021 13F
Filed Feb 14, 2022
|
49 | $515.5M |
|
Q3 2021 13F
Filed Nov 15, 2021
|
46 | $637.3M |
11 earlier quarters on file — choose one from the quarter menu above.
Top 20 holdings · Q1 2026
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | SRRK SCHOLAR ROCK HLDG CORP | $339.1M | 32.95% |
| 2 | MLYS MINERALYS THERAPEUTICS INC | $159.0M | 15.45% |
| 3 | ALMS ALUMIS INC | $139.8M | 13.58% |
| 4 | SEPN SEPTERNA INC | $75.7M | 7.35% |
| 5 | KLRS KALARIS THERAPEUTICS INC | $74.7M | 7.26% |
| 6 | SGP SPYGLASS PHARMA INC | $54.7M | 5.31% |
| 7 | NGNE NEUROGENE INC | $34.6M | 3.36% |
| 8 | IVA INVENTIVA SA | $28.8M | 2.8% |
| 9 | STRO SUTRO BIOPHARMA INC | $26.5M | 2.57% |
| 10 | JBIO JADE BIOSCIENCES INC | $13.6M | 1.32% |
| 11 | VTVT VTV THERAPEUTICS INC | $11.8M | 1.15% |
| 12 | AQST AQUESTIVE THERAPEUTICS INC | $10.4M | 1.01% |
| 13 | XFOR X4 PHARMACEUTICALS INC | $7.6M | 0.74% |
| 14 | NKTX NKARTA INC | $7.4M | 0.72% |
| 15 | ACLX ARCELLX INC | $7.0M | 0.68% |
| 16 | UPB UPSTREAM BIO INC | $6.6M | 0.64% |
| 17 | ABVX ABIVAX SA | $6.3M | 0.61% |
| 18 | AGMB AGOMAB THERAPEUTICS NV | $6.3M | 0.61% |
| 19 | RANI RANI THERAPEUTICS HLDGS INC | $6.2M | 0.61% |
| 20 | CHRS COHERUS ONCOLOGY INC | $5.8M | 0.56% |
Values as reported on the Q1 2026 Form 13F. Every position is in the holdings table below.